Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season

Sanofi will begin to ship their vaccines helping to ensure more people will be immunized

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries

Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants

Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile

Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth

The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

Sanofi India appoints Preeti Futnani as GM, Vaccines

Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.